Background
==========

Human skeletal muscle loss is a common consequence of physical inactivity, immobilization, aging and disease \[[@B1]-[@B5]\]. Two to three weeks of immobilization causes a loss of muscle mass of 5--10%, accompanied by a decrease in strength of 10--20% \[[@B6]-[@B8]\], and, accordingly, individuals with injuries that require immobilization of a limb experience a rapid loss of muscle mass and strength. The recovery from such an injury can be complicated by the lag time for strength recovery and is especially true for vulnerable population groups including older and/or frail adults \[[@B9]\].

Effective and quick rehabilitation of muscle mass and especially strength is of key importance to the immobilized individual. Resistance exercise training and adequate nutrition elicit increased muscle mass and strength \[[@B10]\], and combining resistance exercise and essential amino acids plus carbohydrates enhance muscle protein synthesis to a greater degree than either stimulus alone \[[@B10],[@B11]\]. In addition, discrepant results on the effect of amino acid supplementation on muscle loss with immobilization have been reported \[[@B12],[@B13]\].

Despite the importance of appropriate recovery, the rehabilitation of muscle mass and function following immobilization is understudied \[[@B14],[@B15]\] and whereas the knowledge of muscle mass signaling with immobilization has increased in recent years, there is a paucity of studies on the molecular regulation of muscle mass in the rehabilitation of immobilization-induced muscle atrophy \[[@B7]\].

Muscle mass is regulated by the relative rates of protein synthesis and protein breakdown, and the molecular regulation of this includes the key Akt, mammalian target of rapamycin (mTOR), glycogen synthase kinase 3β (GSK3β) and Forkhead box O (FOXO) signaling pathways \[[@B16],[@B17]\]. Akt is activated by insulin and insulin-like growth factor 1 (IGF-1), and the forced transgenic or pharmacologic induction of Akt *in vivo* or *in vitro* is sufficient to cause dramatic muscle hypertrophy and inhibit atrophy \[[@B18]-[@B22]\]. Akt affects protein synthesis by allowing assembly of a translation initiation complex through GSK3β and mTOR, of which mTOR activates and inhibits its downstream targets ribosomal protein S6 kinase (S6k) and eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1), respectively. Akt also inhibits FOXO transcription factors, which consist of FOXO1, 3 and 4 in skeletal muscle. The activation of FOXO3 induces muscle loss as well as protein degradation and stimulates the transcription of the ubiquitin ligases Atrogin-1 and Muscle Ring Finger protein 1 (MURF1), which together with FOXO1 belong to a set of muscle atrophy-related genes ("atrogenes") that are upregulated in several types of murine muscle atrophy \[[@B18],[@B23]-[@B25]\].

Accordingly, to investigate the phosphorylation and expression of candidate key molecular muscle mass regulators after immobilization and subsequent rehabilitation, we performed two separate studies. First, we immobilized the lower limb for 2 weeks followed by the in-house hospital standard physiotherapy rehabilitation for another 2 weeks. The aim of the first study was to characterize the effects of the immobilization protocol and standard rehabilitation on muscle signaling and mRNA expression (Study 1). Secondly, we conducted an intervention study using the same 2 weeks immobilization protocol during which protein/carbohydrate supplementation was given. This was followed by 6 weeks of rehabilitation in the form of resistance training and continued protein/carbohydrate supplementation. The aim of the second study was to explore the effects of a resistance training and nutrient supplementation based intervention on muscle signaling and mRNA expression during the recovery from immobilization (Study 2). 6 weeks rehabilitation training was selected in order to aim for full recovery of strength and mass. A protocol of 6 weeks of resistance training rehabilitation after 2 weeks of immobilization has been used previously by others investigating the response of the thigh muscles \[[@B7]\].

For Study 1, we hypothesized that the 2 weeks immobilization would decrease Akt and mTOR signaling along with increased FOXO3, Atrogin-1 and MURF1 mRNA expression, reflecting the loss of muscle mass reported previously for this study \[[@B26]\]. Further, we hypothesized that the standard rehabilitation would be insufficient to recover signaling and mRNA expression relative to post-immobilization. For Study 2, we hypothesized (similar to Study 1) decreased Akt and mTOR signaling along with elevated FOXO3, Atrogin-1 and MURF1 transcripts after immobilization. Regarding the subsequent resistance training and protein/carbohydrate supplement based rehabilitation, we hypothesized a full recovery of mass and strength, reflected by a reversal or normalization to basal levels of signaling and mRNA expression. Of note, as Study 1 and Study 2 are separate studies; no comparisons between the two studies are made.

Methods
=======

Study 1: Subjects
-----------------

8 young men (Table [1](#T1){ref-type="table"}) were recruited following online advertising and included in Study 1. As this study also investigated tendon collagen synthesis \[[@B26]\], which is affected by the hormones of contraceptive pills, estradiol and progesterone \[[@B27]\], females were excluded. Eligibility criteria were: Male, 18--30 years of age, no chronic disease, no use of medication, no injuries in the lower body and no obesity (BMI \> 30). Incidentally, all were Caucasians and most of the subjects were recreationally active students. All subjects gave, after receiving oral and written information, written, informed consent to participate in the study, in adherence to the declaration of Helsinki. The study was approved by the local Human Subject Ethics Committee of Copenhagen and Frederiksberg \[(KF) 11 2006--1743\].

###### 

Subject characteristics

  Attribute                  Unit          Study 1   Study 2
  -------------------------- ------------- --------- --------------
  Height                     \(cm\)        184 ± 9   184 ± 7
  Weight                     (kg)          85 ± 12   84 ± 12
  Age                        (years)       23 ± 3    24 ± 3
  BMI                        (kg\*m^-2^)   26 ± 3    25 ± 3
  Bodyfat                    (%)           NR        19.9 ± 5.5
  Self-reported PAL-factor                 NR        1.78 ± 0.36
  Avg. fat intake            \(g\)         NR        69.3 ± 23.8
  Avg. carbohydrate intake   \(g\)         NR        267.5 ± 58.3
  Avg. protein intake        \(g\)         NR        90.3 ± 30.3
  Avg. protein intake        (g/kg)        NR        1.2 ± 0.3

Subject characteristics for Study 1 and Study 2. NR is short for "not recorded". Data are presented as means ± SD.

Study 1: Design
---------------

The subjects were assigned to 2 weeks of immobilizing casting of the lower leg in the non-dominant side, followed by 2 weeks of standard physiotherapy rehabilitation (Figure [1](#F1){ref-type="fig"}), with the other leg serving as a control. Muscle biopsies were sampled 1 week prior to immobilization (PRE), after the 2-week immobilization period (IMMO) and following 2 weeks of rehabilitation (REHAB (2 W)), and from these biopsies mRNA and protein were isolated for use in RT-qPCR and Western blots. Strength and muscle cross-sectional area (CSA) data from this study have been published previously \[[@B26]\].

![**Study setup.** Study setup and flowchart for Study 1 and 2. Muscle biopsies were only taken from the casted leg. All other measurements were bilateral from casted and control legs.](1756-0500-5-166-1){#F1}

Study 1: Standard rehabilitation protocol
-----------------------------------------

Subjects in Study 1 performed 2 weeks rehabilitation as per standard in-house hospital physiotherapy recommendations at the orthopedic department at Copenhagen University Hospital at Bispebjerg. This protocol was selected in order to characterize the effects of a standard rehabilitation course. This protocol is aimed at mobilizing the joint and reactivating neuromuscular and kinesthetic skills, more so than improving tissue protein turnover or muscle metabolism and strength.

Each of the following exercises were to be performed for approximately 60 s daily: 1) slow flexing/stretching of toes, 2) while seated, lifting a cloth off the floor, gripping it with the toes, 3) while seated, slowly sliding the foot back and forth on a cloth, keeping the heel in contact with the floor, 4) while standing, lifting the toes, 5) while standing, doing calf raises, 6) while standing, doing short lunges, performed until the knee passes the toes, 7) straight knee stretching (targeting the gastrocnemius muscle) and 8) bent-knee stretching (targeting the soleus muscle). The subjects did not maintain exercise logs.

Study 2: Subjects
-----------------

In Study 2, another 8 young men (Table [1](#T1){ref-type="table"}) were included from similar advertising and recruiting procedures and on the basis of similar eligibility criteria. All subjects gave, after receiving oral and written information, written consent to participate in the study, in adherence to the declaration of Helsinki. The study was approved by the local Human Subject Ethics Committee of Copenhagen and Frederiksberg \[(H KF) 319605\].

Study 2: Design
---------------

In Study 2, subjects were assigned to an immobilization procedure identical to that used in Study 1, but to another rehabilitation protocol comprised of resistance training for 6 weeks. Moreover, the subjects received protein/carbohydrate supplementation throughout both the immobilization and the rehabilitation period (Figure [1](#F1){ref-type="fig"}).

Muscle biopsies were sampled 1 week prior to immobilization (PRE), following immobilization (IMMO) and following 6 weeks of rehabilitation (REHAB (6 W)) and muscle size was measured by MRI at the same time points. Muscle strength was measured after 2 (REHAB 2 W) and 6 (REHAB (6 W) weeks of rehabilitation and muscle CSA was measured at the REHAB (6 W) time point as well. Muscle strength and size data from the PRE and IMMO time points in this study have been reported elsewhere \[[@B28]\]. Muscle strength and size were measured as described previously \[[@B28],[@B29]\] Briefly, strength was maximal voluntary (isometric) plantarflexion strength with extended knee exerted against a plate connected to a strain gauge, while muscle CSA was measured from MR slice scans 10 cm distal to the caput fibula.

Study 2: Rehabilitation exercise protocol
-----------------------------------------

Subjects in Study 2 performed resistance training directed at increasing strength, muscular endurance and increase connective tissue protein turnover \[[@B26]\] three times a week. During weeks 1 and 2, subjects performed 2x15 (set x repetitions) single-legged standing toe raises at bodyweight with full range of motion and 2x15 toe presses in a seated leg press machine at 15--20 repetition maximum (RM). During weeks 3 and 4, subjects performed 3x15 single-legged standing toe raises with additional 10% bodyweight added and 3x15 eccentric toe presses with progressive weight increases (using both legs in the concentric phase, but only one in the eccentric). During weeks 5 and 6, subjects performed the same number of set and repetitions, but with 20% bodyweight added for toe raises. The training was done supervised in-house at the hospital gym and subjects maintained exercise logs that were validated by instructors.

Study 2: Protein and carbohydrate supplement protocol
-----------------------------------------------------

Prior to immobilization and during the rehabilitation period, subjects in Study 2 maintained food logs for 3 days, which were used to calculate average habitual nutrient and protein intakes (Table [1](#T1){ref-type="table"}).

During the full study (immobilization and rehabilitation), all subjects were instructed to ingest a protein and carbohydrate supplement (20 g of protein and 25 g of dextrose) twice daily and always after exercise. Ingestion of the protein and carbohydrate supplement was monitored only following workouts. The supplement represented a daily addition to protein and energy consumption of 44 and 16%, respectively or an increase in protein consumption of 0.5 ± 0.1 g\*kg^−1^\*day^−1^. Protein/carbohydrate supplementation began on the first day of immobilization and was continued until the last testing session.

The subjects were administered milk protein: 4 were given whey protein (Lacprodan Whey protein isolate, Arla), and 4 were given alpha-lactalbumin (Lacprodan Alpha-10, Arla; a whey subfraction protein), but as statistical endpoint analysis yielded no difference between these protein supplements at any time, they were pooled for all purposes. These two protein supplements have fairly similar amino acid compositions, e.g. both contain 21% branched-chain amino acids.

Immobilization
--------------

In both studies, the ankle joint and lower part of the non-dominant leg was immobilized in a 90° angle using a cast from below the knee to the toes, leaving the Achilles tendon in a neutral position. The subjects were supplied with crutches and instructed to avoid any load-bearing on the immobilized leg. After the 2 weeks of immobilization, the cast was checked for evidence of weight-bearing (any visible damage or marks after load bearing would exclude the subject), removed, and the subjects were tested and sampled again. Following cast removal, subjects were transported in a wheelchair to the MRI facility and back to the laboratory in order to avoid supporting on the immobilized leg prior to muscle biopsy sampling.

Muscle biopsy sampling
----------------------

In both studies, biopsies were sampled from the medial gastrocnemius muscle, using the percutaneous Bergström needle technique \[[@B30]\]. Biopsies were obtained only from the casted leg and not the control leg. Before taking the biopsies, ultrasound imaging was used to identify areas of the muscle with large vessels that should be avoided during the sampling, to prevent unnecessary intramuscular hematomas. Individual biopsy sites were moved 2--3 cm between repeated samplings. In both studies, subjects were sampled at the PRE, IMMO and REHAB time point, with REHAB being after 2 weeks of rehabilitation in Study 1 and after 6 weeks in Study 2.

RNA isolation
-------------

In both studies, approximately 10 mg of muscle tissue was used for RNA isolation. RNA was isolated using phenol extraction \[[@B31]\], using the Trizol kit (Tri-Reagent, Molecular Research). The isolation was performed essentially as proposed, but with two subsequent ethanol precipitation steps, rather than one. The tissue homogenization step was performed using a bead beater (Fastprep-24, MP Biomedicals) shaking specimens in 1 ml Trizol in a 2 ml Biospec tube with 5 stainless steel beads (2.3 mm) and 5 silicon carbide grains for 15 s at speed 4.0 twice. Between shakings samples rested in an ice-water bath. RNA integrity was measured by electrophoresis, running 200 nanograms of RNA on a denaturing agarose gel and visualized with SYBR Green II staining.

Realtime RT-qPCR
----------------

In both studies, the mRNA expression of FOXO4 and the atrophy-related genes FOXO1, FOXO3, Atrogin-1 and MURF1 \[[@B23],[@B25]\] was analyzed by real-time RT-qPCR. Total RNA (500 ng) was converted into cDNA in 20 μl using the OmniScript reverse transcriptase kit (Qiagen, CA, USA) and poly-dT according to the manufacturer's protocol. For each target, 0.25 μl cDNA was amplified in a 25 μl SYBR Green PCR reaction containing 1X Quantitect SYBR Green Master Mix (Qiagen) and 100 nM of each primer (Table [2](#T2){ref-type="table"}). The amplification was monitored real-time using the MX3000P real-time PCR machine (Stratagene). The threshold cycle (Ct) values were related to a standard curve made with the cloned PCR products and specificity ensured by melting curve analyses.

###### 

Antibody and primer specifications

  ***Primary Antibodies***                                                                             
  ---------------------------- ------------------------- ----------------------------- --------------- ------------
  *Epitope*                    *Manufacturer*            *Catalog no.*                 *Dilution*      
  Akt                          Cell Signaling            2920                          1:2,000         
  p-Akt (T308)                 Cell Signaling            2965                          1:2,000         
  p-Akt (S473)                 Cell Signaling            4060                          1:2,000         
  mTOR                         Cell Signaling            2983                          1:2,000         
  p-mTOR (S2448)               Cell Signaling            2971                          1:2,000         
  p-mTOR (S2481)               Cell Signaling            2974                          1:2,000         
  S6K                          Cell Signaling            9202                          1:2,000         
  p-S6K (T389)                 Cell Signaling            9206                          1:2,000         
  GSK3β                        Abcam                     Ab31826                       1:2,000         
  P-GSK3β (S9)                 Cell Signaling            9336                          1:2,000         
  4E-BP1                       Santa Cruz                Sc-81149                      1:200           
  p-4E-BP1 (T37/46)            Cell Signaling            2855                          1:2,000         
  MURF1                        Abcam                     Ab4125                        1:2,000         
  ***Secondary antibodies***                                                                           
  *Epitope*                    *Fluorophore conjugate*   *Manufacturer*                *Catalog no.*   *Dilution*
  Mouse Ig                     Alexa 680                 Invitrogen                    A21057          1:10,000
  Goat Ig                      Alexa 680                 Invitrogen                    A21084          1:10,000
  Rabbit Ig                    Dylight 800               Pierce                        35571           1:10,000
  ***PCR primers***                                                                                    
  *Target*                     *Primers*                                                               
  FOXO1                        Sense                     GCCCAACCAAAGCTTCCCACAC                        
                               Antisense                 TGGACTGCTTCTCTCAGTTCCTGCT                     
  FOXO3                        Sense                     GCTGGGTGCCAGGCTGAAGG                          
                               Antisense                 TTGGCAAAGGGTTTTCTCTGTAGGT                     
  FOXO4                        Sense                     GATGAGGGCGAGGGACTGGA                          
                               Antisense                 TCCACATCTGAAGCAGGGGACA                        
  MURF1                        Sense                     TGGGGGAGCCACCTTCCTCT                          
                               Antisense                 ATGTTCTCAAAGCCCTGCTCTGTCT                     
  Atrogin-1                    Sense                     TGTTACCCAAGGAAAGAGCAGTATGGA                   
                               Antisense                 ACGGAGCAGCTCTCTGGGTTATTG                      
  HADHA                        Sense                     GCGAGTCTGAAGCTGCCTCCTAA                       
                               Antisense                 GGCACATGACTGCCTCATTCACA                       
  S26                          Sense                     AACACCCCCACCCCGATTTAGAC                       
                               Antisense                 GAACTCAGCTCCTTACATGGGCTTT                     
  Cyclophillin                 Sense                     TGCAGACAAGGTCCCAAAGACAG                       
                               Antisense                 TGAAAGCAGGAACCCTTATAACCA                      
  β2-microglobulin             Sense                     GCTGTGCTCGCGCTACTCTCTCT                       
                               Antisense                 TCTGCTGGATGACGTGAGTAAACCT                     
  GAPDH                        Sense                     CCTCCTGCACCACCAACTGCTT                        
                               Antisense                 GAGGGGCCATCCACAGTCTTCT                        

Specification of antibodies used for Western blots and primers used for qPCR.

In the initial PCR assay we measured Glyceraldehyde 3-phosphate dehydogenase (GAPDH) and Ribosomal protein, large, P0 (RPLP0) expression for normalization purposes, but as their expression changed in relation to each other, we proceeded to measure more putative housekeeping genes (26S, β2-microglobulin, Cyclophillin A and HADHA) in another assay. Therefore, we measured expression of six putatively stably expressed "housekeeping" genes GAPDH, RPLP0, β2-microglobulin (β2MG), Cyclophillin A, hydroxyacyl-coenzyme A dehydrogenase alpha subunit (HADHA) and ribosomal protein S26 (S26) and did indeed find significant variation within these supposedly stably expressed genes (See Results section). Thus, we proceeded to use the "GeNorm" algorithm (VBA applet for Excel) \[[@B32]\] to identify the housekeeping genes most stably expressed. The GeNorm housekeeping gene analysis revealed the most variable genes to be GAPDH, S26 and HADHA in descending order of variability. Including β2MG, RPLP0 and Cyclophillin A in the geometric mean used for normalization yielded a variability score of 0.151, complying with the "stability threshold" score of 0.150 recommended in Vandesompele et al. \[[@B32]\]. We proceeded to generate geometric means of the expression of these genes and used the resulting figure for normalization. Statistics were done on normalized and log-transformed numbers. Finally, we back-transformed means and SEM's for reporting and graphical visualization.

Protein isolation
-----------------

Approximately 10 mg of muscle tissue was homogenized as described for RNA isolation, but performed in 200 μl homogenization buffer (50 mM Tris--HCl, 1 mM EDTA, 1 mM EGTA, 10 mM β-glycerophosphate. 50 mM NaF, 0.5 mM sodium orthovanadate, 0.1% 2-mercaptoethanol, 0.1% Triton-X and protease inhibitor (Complete, Roche), adjusted to pH 7.5). Following bead beating, samples were briefly spun down and aliquots of the resulting supernatant were used for protein concentration determination, using the EZQ protein quantitation kit (Molecular Probes) and CCD camera (Kodak Image Station 3000MMpro). Prior to loading, aliquots of the samples were diluted to a final concentration of 1 ug/ul, using 4X Laemmli buffer, to a final concentration of 1X Laemmli.

Western blots
-------------

In both studies, we measured total protein and phosphorylation for Akt (T308 and S473), mTOR (S2448 and S2481), S6k (T389), 4EBP1 (T37/46) and GSK3β (S9) as well as protein expression of ubiquitin and MURF1 (Table [2](#T2){ref-type="table"}). Western blotting was performed essentially as previously described \[[@B33]\]. For electrophoresis, 20 μg protein per well was loaded on Criterion 4--12% gradient gels (Bio-Rad) and run at 200 V for 1 h. The gels were cut into pieces corresponding to target sizes. Gel slabs containing proteins larger than 110 kDa were blotted in absence of methanol, while the remaining gel pieces were blotted in the presence of methanol. Gels were blotted (Trans-blot cell, Bio-Rad, 400 mA, 2 h) to polyvinylidene difluoride membranes (Amersham Hybond LFP, GE Healthcare) in transfer buffer (50 mM Tris-base, 383 mM glycine, 20% v/v methanol), washed briefly in distilled water and blocked for 30 min in 10% Odyssey Blocking buffer in phosphate-buffered saline (PBS). Following blocking, membranes were washed in Tris-buffered saline with Tween-20 (TBST) (50 mM pH 7.4 Tris, 150 mM NaCl, 0.1% Tween-20, pH 7.4) and incubated with primary antibodies (Table [2](#T2){ref-type="table"}) overnight. Following primary antibody incubation, membranes were washed in TBST and incubated with appropriate secondary antibodies conjugated to Dylight 800 or Alexa 680 fluorophores (Table [2](#T2){ref-type="table"}). For visualization, blots were scanned using an Odyssey scanner (LiCor) at 84 μm resolution and standard settings and quantified using ImageJ (National Institutes of Health, USA). Where appropriate, total and phospho-antibodies were incubated simultaneously on the same membrane, each in its own wavelength channel. Prior to statistical analysis, results were normalized to individual PRE values and log-transformed. Finally, we back-transformed means and SEM's for reporting and graphical visualization.

Statistics
----------

No statistical comparisons were made between Study 1 and 2, as we consider them separate studies. Statistical analysis was, however, performed in an identical manner between the two studies.

For Study 2 only, muscle size (CSA) and strength (MVC) PRE-normalized data were subjected to repeated measures one-way ANOVA (and post hoc testing) individually for each leg.

Western blot and RT-qPCR data were normalized as described in their respective paragraphs and log-transformed prior to being subjected to repeated measures one-way ANOVA (and post hoc testing). The log-transformation was used to ensure that the data approached normal distribution as closely as possible.

In figures, all data are presented as means ± SEM (for RT-qPCR and Western blot data back-transformed means ± SEM). In Table [1](#T1){ref-type="table"}, data are presented as means ± SD. CSA, MVC and mRNA analyses were done using Sigmastat 3.5.0.54 (Systat Software, 2006) with Student-Newman-Keuls correction for multiple testing, whereas protein data were analyzed using SAS 9.1.3 (SAS Institute 2008). For all post hoc tests we applied a significance threshold of 0.05.

Results
=======

Study 1
-------

### mRNA expression

As for mRNA (Figure [2A](#F2){ref-type="fig"}), we observed significant time effects for FOXO3 (*p* = 0.004), FOXO4 (*p* = 0.013), GAPDH (*p* = 0.005), HADHA (*p* = 0.010) and S26 (*p* = 0.037) transcripts. For FOXO3 and FOXO4 this was manifested in the form of a downregulation at the IMMO time point (−40% for FOXO3 (*p* = 0.006) and −58% for FOXO4 (*p* = 0.026)) that persisted until the REHAB (2 W) time point (−19% for FOXO3 (*p* = 0.006) and −35% for FOXO4 (*p* = 0.009)). GAPDH and HADHA were also downregulated at the IMMO time point (−53% for GAPDH (*p* = 0.004) and −40% for HADHA (*p* = 0.008)), but returned almost back to baseline expression at the REHAB time point. Despite manifesting a time effect, S26 was not significantly downregulated at either time point (Figure [2A](#F2){ref-type="fig"}).

![**Data for Study 1. A:** mRNA expression measured by RT-qPCR. mRNA data are normalized to geometric means of Cyclophillin A, β2-microglobulin and RPLP0 and are relative to individual PRE values. Target genes are presented in the left side panel, whereas putative housekeeping genes are presented in the right side panel. Data are presented as back-transformed mean ± SEM. Light gray columns represent IMMO and dark gray REHAB. **B:** Total protein and protein phosphorylation measured by Western blot, relative to individual PRE values. Data are presented as back-transformed mean ± SEM. Total Akt is represented twice as it was measured along with each phospho-Akt. Light gray columns represent IMMO and dark gray REHAB. \* denotes a difference from PRE with 0.05 \> *p* ≥ 0.01. \*\* denotes a difference from PRE with 0.01 \> *p* ≥ 0.001. Underscored asterisks denote main (time) effects.](1756-0500-5-166-2){#F2}

### Protein expression and phosphorylation

Despite the obvious changes in muscle mass \[[@B26]\], we observed no significant modulation of total or phosphoprotein levels of Akt, GSK3β, 4EBP1, ubiquitin or MURF1 in Study 1 (Figure [2B](#F2){ref-type="fig"}). Total and phosphorylated levels of mTOR and S6k were below the detection threshold.

Study 2
-------

### Muscle strength and size

In Study 2, we report additional muscle strength and size data for the REHAB time points. For strength, no significant time effects were detected in either leg. Following 2 and 6 weeks of rehabilitation, strength was elevated to levels slightly higher than those recorded before immobilization, but these differences did not reach significance. For muscle size, no differences were observed between the REHAB (6 W) time point and PRE.

### mRNA expression

For mRNA (Figure [3A](#F3){ref-type="fig"}), we observed time effects for FOXO1 (*p* = 0.030), Atrogin-1 (*p* = 0.046), GAPDH (*p* = 0.001), HADHA (*p* = 0.035) and S26 (*p* = 0.001). Notably, for neither FOXO1 nor Atrogin-1, the main effect could be observed as deviations from PRE. For both GAPDH and HADHA, we observed a downregulation at the IMMO time point (−39% for GAPDH (*p* = 0.001) and −24% for HADHA (*p* = 0.043)) and a subsequent return to baseline expression, whereas for S26 we found a downregulation at the IMMO time point that persisted throughout the REHAB (6 W) time point (−26% at IMMO (*p* = 0.002) and −20% at REHAB (*p* = 0.006) (Figure [3A](#F3){ref-type="fig"}).

![**Data for Study 2. A:** mRNA expression measured by RT-qPCR. mRNA data are normalized to geometric means of Cyclophillin A, β2-microglobulin and RPLP0 and are relative to individual PRE values. Target genes are presented in the left side panel, whereas putative housekeeping genes are presented in the right side panel. Data are presented as back-transformed mean ± SEM. Light gray columns represent IMMO and dark gray REHAB. **B:** Total protein and protein phosphorylation measured by Western blot, relative to individual PRE values. Data are presented as back-transformed mean ± SEM. Total Akt is represented twice as it was measured along with each phospho-Akt. Light gray columns represent IMMO and dark gray REHAB. \* denotes a difference from PRE with 0.05 \> *p* ≥ 0.01. \*\* denotes a difference from PRE with 0.01 \> *p* ≥ 0.001. Underscored asterisks denote main (time) effects.](1756-0500-5-166-3){#F3}

### Protein expression and phosphorylation

Contrary to the changes in muscle mass reported previously \[[@B28]\], we found no significant modulation of total or phosphoprotein levels of Akt, GSK3β, 4EBP1, ubiquitin or MURF1 in Study 2 (Figure [3B](#F3){ref-type="fig"}). Total and phosphorylated levels of mTOR and S6k were below the detection threshold.

Discussion
==========

For Study 1, we hypothesized that the 2 weeks immobilization would decrease Akt and mTOR signaling along with increased FOXO3, Atrogin-1 and MURF1 mRNA expression, reflecting the loss of muscle mass previously reported for this study \[[@B26]\]. We observed no changes in Akt and mTOR signaling, and of FOXO3, Atrogin-1 and MURF1 only FOXO3 was significantly downregulated after immobilization, which is opposite of what we expected. Furthermore, we hypothesized that the standard rehabilitation would be insufficient to recover signaling and mRNA expression relative to post-immobilization. As hypothesized, signaling and all mRNAs, except the downregulated FOXO3, were unchanged with rehabilitation relative to the IMMO time point.

For Study 2, we hypothesized (similar to study 1) decreased Akt and mTOR signaling along with elevated FOXO3, Atrogin-1 and MURF1 transcripts after immobilization. Unexpectedly, Akt and mTOR signaling and the measured mRNAs remained unchanged after immobilization. Regarding the subsequent combined resistance training and protein/carbohydrate supplementation based rehabilitation, we hypothesized a full recovery of mass and strength, reflected by a reversal or normalization to basal levels of signaling and mRNA expression. Indeed, this rehabilitation protocol restored both mass and strength, whereas signaling and mRNA expression remained unchanged after rehabilitation relative to post-immobilization.

Protein expression and phosphorylation
--------------------------------------

To our knowledge, we present the first results on Akt, 4E-BP1 and GSK3β phosphorylation following rehabilitation after immobilization, and, unexpectedly, we show no changes. Contrary to our hypothesis for both Study 1 and Study 2, the total and phosphorylation levels of the measured proteins remained unchanged after 2 weeks immobilization. This is similar to a previous human 10 days immobilization study reporting unchanged total and phosphorylated levels of Akt, S6k and 4E-BP1 \[[@B6]\], although a decrease in Akt S473 phosphorylation after 20 days immobilization has been observed as well \[[@B34]\]. Of note, these studies \[[@B6],[@B34]\] were performed on vastus lateralis muscle, whereas our data is generated from gastrocnemius muscle, which may affect the response. Moreover, the high variation in the data may explain, at least partly, the absence of significant differences with time or treatment (Figures [2B](#F2){ref-type="fig"} and [3B](#F3){ref-type="fig"}). Due to this variation we cannot exclude the possibility that some minor modulation occurs, but it is unlikely that the observed variation masks large changes in phosphorylation status.

mRNA expression
---------------

Unexpectedly, we observed a significant decrease in FOXO3 and FOXO4 mRNA expression with immobilization as well as rehabilitation in Study 1 (Figure [2A](#F2){ref-type="fig"}). This could be interpreted as an anti-catabolic response, but given that the subjects were atrophic at the IMMO time point \[[@B26]\] and anabolic at the REHAB time point, this represent a discrepancy between the suggested gene function and the physiological condition. We cannot rule out the possibility that this response is secondary to other regulation events and thus not part of a primary response. It is still a matter of debate what the individual biological contributions of each FOXO gene are and under what circumstances they are activated, but murine *in vitro* and *in vivo* studies indicate that the FOXO genes should be considered negative regulators of muscle mass \[[@B20],[@B35]-[@B37]\].

FOXO transcript behavior *in vivo* is poorly characterized with immobilization and our data represent novel findings on the effects of immobilization and rehabilitation on FOXO transcript regulation in human muscle. Regarding the sparse literature that does exist, FOXO3 reporter activity has been shown to be upregulated with immobilization in an animal model \[[@B38]\], whereas in a human model, 3 and 20 days of unloading produced no changes in FOXO1 or FOXO3 mRNA and protein expression levels \[[@B34],[@B39]\].

As for the "atrogenes" Atrogin-1 and MURF1 \[[@B18],[@B23]\], in Study 2, we observed a tendency (*p* = 0.10) towards an increase from PRE in Atrogin-1 expression (Figure [3A](#F3){ref-type="fig"}) after immobilization. Both Atrogin-1 and MURF1 have previously been shown to be upregulated in a 14-day human immobilization study \[[@B7]\], although in that study, the upregulation of MURF1 did not reach statistical significance. Other time course studies show that Atrogin-1 and/or MURF1 expression increases in the initial phase of immobilization and gradually declines, sometimes even to levels below baseline \[[@B6],[@B40]\]. Also, in the study by Jones et al. \[[@B7]\], Atrogin-1 and MURF1 seem to return to pre-levels with rehabilitation like in the present study, but with an apparent "undershoot", a finding we cannot replicate due to our less detailed time course.

Normalization of mRNA expression
--------------------------------

In the initial PCR assay we measured GAPDH and RPLP0 expression for normalization purposes, but as their expression changed in relation to each other, we proceeded to measure more putative housekeeping genes (26S, β2-microglobulin, Cyclophillin A and HADHA) in another assay. Actually, we have previously shown that our most frequently used normalization genes RPLP0 and GAPDH change in rats with hindlimb unloading, relative to muscle weight as well as relative to total RNA \[[@B41]\]. Accordingly, we used the method suggested by Vandesompele et al. \[[@B32]\] to determine which genes were the most stably expressed and used those for normalization. This analysis indicated GAPDH, HADHA and S26 to be the most variable of the measured housekeeping genes. Indeed, in both of our immobilization experiments, all of these genes displayed decreases in expression with immobilization, with GAPDH actually returning to baseline levels after rehabilitation (Figures [2A](#F2){ref-type="fig"} and [3A](#F3){ref-type="fig"}), thereby making these genes highly unsuitable for normalization purposes in immobilization studies. This is particularly relevant for GAPDH, being one of the most common normalization genes used and due to it responding drastically to immobilization, thereby not being fit for normalization purposes. This may have implications for interpretation of existing immobilization studies using GAPDH as an internal reference in RT-qPCR analyses without further validation of housekeeping gene expression stability \[[@B42]-[@B44]\], and should most certainly be kept in mind in future immobilization studies measuring mRNA expression.

Limitations
-----------

The discontinuous nature of these studies represents a major limitation. The missing time points and discrepant time courses do not allow for interstudy comparison, which would otherwise have been informative. Moreover, using the contralateral limb as a control in immobilization studies is controversial as the contralateral limb may experience a compensatory training effect due to increased stress \[[@B45]\]. This is especially true when combined with protein/carbohydrate supplementation as this is thought to contribute to hypertrophy only in conjunction with exercise or increased workload \[[@B46]\]. Therefore, the contralateral leg cannot be considered a true, passive control within this study.

The variation in our Western blots was higher than expected; part of this can likely be ascribed to keeping our stock samples in a native buffer. Since then, we have found that denaturing samples immediately following sample homogenization yields more consistent results.

In Study 1, no exercise logs were maintained, and this could mask low compliance, which in turn could cause impaired rehabilitation efficiency. Moreover, it must be noted that the ingestion of supplements were only supervised on post-workout occasions, allowing for compliance issues.

Conclusions
===========

In Study 2, we observed full strength recovery after 2 weeks of rehabilitation. In both studies, no changes in protein expression or phosphorylation for any measured protein were observed. In Study 1, FOXO3 and FOXO4 mRNA expression decreased after IMMO and REHAB compared to PRE, whereas other mRNAs remained unchanged. Interestingly, we found significant changes in expression of the putative housekeeping genes GAPDH, HADHA and S26 with immobilization in both studies.

Accordingly, in either study, changes in muscle mass after immobilization and subsequent rehabilitation were not reflected in total protein or phosphorylation status of Akt and mTOR pathway components. The changes in the so-called housekeeping genes GAPDH, HADHA and S26 with immobilization in both studies question the usefulness of these genes for normalization purposes in muscle immobilization studies, and a more thorough characterization of changes in housekeeping genes is of relevance to future immobilization studies.

In perspective, this calls for further research, preferably a full randomized controlled trial, comparing the contributions of protein/carbohydrate supplementation and resistance training, individually as well as in combination, on immobilization-induced atrophy and rehabilitation-induced hypertrophy and related molecular regulation.
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